Compare Allstate Corp (ALL) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Allstate Corp vs Gilead Sciences, Inc. — how do they compare? Allstate Corp trades at $252.97 (market cap $64.77B), while Gilead Sciences, Inc. trades at $130.85 (market cap $161.19B). The key difference: Gilead Sciences, Inc. is far larger — about 2.5× Allstate Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.53%). Which is the better fit depends on your goals.
| ALL | GILD | |
|---|---|---|
Market Cap | $64.77B | $161.19B |
Sector | Financials | Health |
52-Week High | $251.61 | $155.80 |
52-Week Low | $190.00 | $108.22 |
Enterprise Value | $73.56B | $175.72B |
Dividend Yield | 1.72% | 2.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allstate (ALL) trades at $251.61, up 1.19% on the day, with a bullish technical outlook and strong fundamental momentum. The stock shows robust earnings beats in recent quarters, a low P/E of 5.57, and a high ROE of 48.44%. Recent news highlights dividend declarations and anticipation for Q2 2026 earnings, with analysts citing improved underwriting and catastrophe performance as key drivers.
The outlook remains positive given valuation discounts and earnings growth, but risks include hurricane season exposure and competitive pressures. Upside potential is supported by a consensus price target of $251.18, with Wall Street largely holding a buy or neutral stance, though near-term volatility may arise from earnings results due August 6, 2026.
Gilead Sciences (GILD) trades at $129.83, down 3.72% on the day, with a bullish technical signal and strong fundamentals including a 30.99% net income margin and 43.19% ROE. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer expand its oncology portfolio, while earnings have consistently beaten estimates in recent quarters. The stock shows robust profitability and cash flow generation despite a net cash outflow in 2025.
Outlook remains positive with a consensus price target of $154.57 (19% upside), supported by analyst bullishness (67% buy ratings) and growth catalysts in HIV and oncology. Key risks include patent expirations for key drugs and competitive pressures in the biotech sector. The valuation at 17.66x P/E appears reasonable given earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allstate Corp
On the basis of premium sales, Allstate is one of the largest U.S. property and casualty insurers. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 agencies.
Read more on ALL →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
